Eterna (ERNA) Therapeutics announced the addition of Jerome Zeldis, M.D., Ph.D., and Blythe Sather, Ph.D., to the company’s scientific advisory board. With their deep insight and experience in cell therapy, Dr. Zeldis and Dr. Blythe will play a role in advancing ERNA-101 in solid tumors and ERNA-102 in autoimmune diseases through their preclinical studies.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERNA: